We chose LILRB2 (14), VNN2 (15), and KLF4 (16) as LSC markers since they exhibited higher expression levels in AML patients compared with normal volunteers in TCGA database and the Genotype-Tissue Expression (GTEx) project (Figure 1G). Here, VNN2 is linked to acute myeloid leukemia.